Development
Boston Scientific Corporation
BSX
$102.83
$0.400.39%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.24B | 13.76B | 13.40B | 13.05B | 12.68B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.24B | 13.76B | 13.40B | 13.05B | 12.68B |
| Cost of Revenue | 4.39B | 4.26B | 4.14B | 4.09B | 4.00B |
| Gross Profit | 9.85B | 9.50B | 9.27B | 8.96B | 8.68B |
| SG&A Expenses | 5.19B | 4.97B | 4.86B | 4.68B | 4.52B |
| Depreciation & Amortization | 829.00M | 820.00M | 814.00M | 808.00M | 803.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.83B | 11.43B | 11.18B | 10.91B | 10.65B |
| Operating Income | 2.42B | 2.32B | 2.22B | 2.13B | 2.03B |
| Income Before Tax | 1.98B | 1.88B | 1.51B | 1.43B | 1.14B |
| Income Tax Expenses | 393.00M | 647.00M | 599.00M | 528.00M | 442.00M |
| Earnings from Continuing Operations | 1.59K | 1.23K | 912.00 | 902.00 | 698.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00M | -- | -- | -- | -- |
| Net Income | 1.59B | 1.23B | 912.00M | 902.00M | 698.00M |
| EBIT | 2.42B | 2.32B | 2.22B | 2.13B | 2.03B |
| EBITDA | 3.61B | 3.50B | 3.38B | 3.28B | 3.17B |
| EPS Basic | 1.08 | 0.82 | 0.60 | 0.59 | 0.45 |
| Normalized Basic EPS | 0.91 | 0.89 | 0.83 | 0.81 | 0.67 |
| EPS Diluted | 1.07 | 0.82 | 0.60 | 0.59 | 0.45 |
| Normalized Diluted EPS | 0.90 | 0.88 | 0.83 | 0.80 | 0.66 |
| Average Basic Shares Outstanding | 5.81B | 5.78B | 5.75B | 5.73B | 5.72B |
| Average Diluted Shares Outstanding | 5.85B | 5.82B | 5.78B | 5.77B | 5.76B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.76% | 3.34% | 6.03% | 6.10% | 7.88% |